RxDoctor Payments Data

Dina Block, MD

Endocrinology, Diabetes & Metabolism · Beverly Hills, CANPI 1497996318

Payments from drug & device makers

$1,746in general payments, 2019–2025

Across 83 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$588
  • Lilly USA, LLC$300
  • Insulet Corporation$245
  • AbbVie$93
  • Boehringer Ingelheim$81
  • Abbott$73
  • plus $366 from 9 others

What the payments were for

  • Food & beverage$1,73499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,746 in reported general payments places this provider in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$44,271
Medicare patients
169
Services billed
418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide143$171,379
OzempicSemaglutide81$86,533
JardianceEmpagliflozin88$85,053
TrulicityDulaglutide44$39,533
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/721$19,980
Tresiba Flextouch U-100Insulin Degludec33$18,882
JanuviaSitagliptin Phosphate18$14,442
SynthroidLevothyroxine Sodium60$5,017
Nano 2nd Gen Pen NeedlePen Needle, Diabetic20$2,475
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic21$1,147
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,021
Levothyroxine Sodium91$964
Droplet Pen NeedlePen Needle, Diabetic12$830
Testosterone11$573
Hydrocortisone25$562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$300$210,911187 claims
Novo NordiskOzempic$588$86,53381 claims
Boehringer IngelheimJardiance$81$85,05388 claims
AbbVieSynthroid$93$5,01760 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →